FooterNews

29th November 2022 – Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility

by

29th November 2022 – Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, … Read more

Newsletter – November 16th 2022

by

Upperton Launches ASAPprime® Shelf-Life Stability Testing Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the … Read more

Newsletter – September 15th 2022

by

In Vitro Testing of Dry Powder Nasal Delivery Devices Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the … Read more

Newsletter – August 16th 2022

by

Latest News from Upperton Pharma Solutions Successful MHRA Inspection Upperton is delighted to announce that during the last week of July 2022 the UK MHRA conducted a routine, three day inspection of the GMP facility and Quality Control testing laboratories following which, no Critical or Major observations were raised. Speaking after the inspection, CEO Nikki … Read more

Newsletter – June 23rd 2022

by

Characterising the physical properties of spray dried powders The benefits of powder characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases … Read more

23rd May 2022 – Upperton Pharma Solutions announces £15m investment in new facilities

by

Upperton Pharma Solutions announces £15m investment in new facilities Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham. The new facilities will allow a significant increase in research and development laboratory space … Read more

21st April 2022 – Inflexion announces investment into Upperton

by

21st April 2022 – Inflexion announces investment into Upperton Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who … Read more

5th April 2022 – Upperton Pharma Solutions launches nasal delivery development platform

by

5th April 2022 – Upperton Pharma Solutions launches nasal delivery development platform Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal … Read more

20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery

by

Article 20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery Formulation Options In Nasal Drug Delivery Upperton had an article published in Edition 119 ONdrugDeliver in May 2021 In the article Richard Johnson, CEO and founder of Upperton,  discusses the advantages of nasal delivery and why there is growing interest in this route … Read more

29th April 2021 – Formulation Options in Nasal Drug Delivery

by

News 29th April 2021 – Formulation Options in Nasal Drug Delivery Nasal delivery offers a number of unique opportunities for the successful delivery of drugs and vaccines either locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via … Read more

Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.

Quick Links

Contact Us

Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: contact@upperton.com